在心肌梗塞和治疗挑战期间离子通道的动态变化
Tongtong Song1,2, Wenting Hui1, Min Huang1
1Department of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun 130012, China.
International journal of molecular sciences
|June 27, 2024
概括
心肌梗塞 (MI) 改变了心脏细胞中的离子通道表达,影响了心脏节律和修复. 本综述探讨了MI诱导的离子通道变化和治疗心脏病的治疗策略.
科学领域:
- 心血管生理学心血管生理学
- 分子心脏病学分子心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏中的动能波形因离子通道 (,,) 的差异表达而有所不同.
- 心肌梗塞 (MI) 破坏氧气平衡,导致离子失衡,并改变心肌细胞,纤维细胞和免疫细胞中的离子通道表达.
- 这些离子通道变化会影响心律,心肌损伤和修复过程.
研究的目的:
- 审查心肌梗塞 (MI) 后各种离子通道的变化.
- 讨论针对这些离子通道的治疗药物.
- 分析心肌离子通道调节的分子机制和药物治疗中的挑战.
主要方法:
- 对MI后离子通道表达和功能研究的文献综述.
- 对心脏细胞中离子通道调节的基础分子机制的分析.
- 检查针对离子通道的当前和潜在的治疗干预措施.
主要成果:
- MI显著改变心肌细胞中K+,Ca2+和Na+离子通道的表达和功能,影响心脏电生理学.
- 心肌纤维细胞和免疫细胞在心肌梗塞后也表现出改变的离子通道活性,影响修复和信号传递.
- 离子通道是开发针对心脏病发作和相关心脏病的新型治疗策略的关键目标.
结论:
- 了解MI诱导的离子通道失调是开发有效治疗的关键.
- 准心肌细胞,纤维细胞和免疫细胞中的离子通道提供了有希望的治疗途径.
- 需要对分子机制和药物开发进行进一步的研究,以克服对MI的离子通道疗法的挑战.
相关概念视频
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
01:26Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
965
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
965
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486
01:30Cardiac Action Potential
1.3K
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
1.3K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823